Physician profile
Candy N Ting
NPI 1558330035
$28,323.53
in general payments reported to CMS, 2019-2025
61 companies · $3,585 in 2025
The $3,585 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,924 · 2020: $2,084 · 2021: $1,054 · 2022: $1,779 · 2023: $3,240 · 2024: $12K · 2025: $3,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,985 · Travel and Lodging: $1,091 · Education: $31.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,376.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,985.00 |
| Travel and Lodging | $1,090.89 |
| Education | $31.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $7,920.17 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $3,893.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,747.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,910.92 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $1,415.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $995.70 | 2019-2025 | |
| Abbvie INC. | $961.23 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $918.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $866.99 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Janssen Pharmaceuticals, INC | $508.11 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $466.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $453.92 | 2019-2022 | |
| Corium, LLC | $451.15 | 2023-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.73 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $271.41 | 2023-2025 | Cologuard Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candy Ting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.